2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sittenHave been in since it was called Nano, and lost a bit on it. Have been in after they changed their name to Thor Medical. Now the risk is minimized. A company with the same technology may emerge, but Thor is first out, and there will be room for more. The demand for Thorium will increase as existing and new companies get approval for their cancer medicines. That can happen at any time.
I was so lucky to be part of NANO's fantastic journey from when the price was about 14-16 until I sold out at around 114, a good year later!! though it probably had a peak at around 120!. As far as I remember. Hope and believe the story can repeat itself :-)
·4 t sittenhttps://youtu.be/G7N_DWUxLXw?is=7sIGK6n87SHns3Bv Jasper in the studio at FA. Sounds positive all the way through👍
·7 t sittenAsked chatgpt to estimate stock price in 10 years. Where A1-2 and global are involved. This was a slightly more simplified answer: ### Thor Medical – realistic 10-year scenario (2036) **Assumptions** * AlphaOne: 21 000 doses. * AlphaTwo: approx. 200 000 doses. * AlphaGlobal: >1 million doses. * Price per dose follows 2,5 % inflation: **16 000 kr → approx. 20 500 kr in 2036**. * Two share issues totaling approx. **1 billion kr**, so that the number of shares increases from around **330 to approx. 500 million**. ### Timeline * **2026–2027:** AlphaOne in commercial operation. * **2028:** Share issue and construction start AlphaTwo. * **2030:** AlphaTwo in production. * **2032:** New share issue/partnership for AlphaGlobal. * **2034–2035:** AlphaGlobal in operation. * **2036:** Full global capacity. ### Possible financials in 2036 * **Revenue:** 22–26 billion kr. * **Net profit:** 9–12 billion kr. * **Market capitalization:** 180–250 billion kr (P/E 20–25). * **Share price:** **360–500 kr** (with approx. 500 million shares). ### Realistic drawbacks * Share issues will likely dilute current shareholders. * Price per dose may fall if competition increases. * Construction of new factories may become more expensive or delayed. * Approvals and customer adoption may take longer than planned. * Several companies are developing alternative production methods and isotopes. ### Conclusion If Thor Medical succeeds in becoming a dominant player and implements the scaling as planned, a **long-term price range of 350–500 kr** appears as an optimistic, but still plausible scenario. If growth is weaker or dilution greater than assumed, the valuation may be significantly lower. Conversely, an even stronger market position and higher profitability could yield higher values than this range.
There are so many scenarios and limitations that ChatGPT does not account for. The most common (in the West) are directed issues to only larger shareholders (note that this is something Thor has not done so far), the company can be acquired where we small investors are kicked out, any positive cash flow quickly faces strong competition, even better and newer technology than Thor's method will emerge. Furthermore, there are already approximately 360 million shares today, and with A-Two and A-Global, this will require large investments, meaning far more than a total of 500 million shares. We will be heavily diluted, and with dilution, the share price will normally fall. I believe that for us small investors, a horizon of 2-5 years is more sensible, and then we can extend the horizon when one sees that the landscape allows for it. My prediction is that we will be rising in the 6s this autumn, and rising in the 7s after the Q4 report in February 2027. Thor must now prove its position and its cash flow. The time for only expectations, faith, hope, and love is now over. Only real money in the till matters from this autumn, P/E.
·8 t sittenUp approx 6% today kr 5.64 is somewhat weak with such very good news and a healthy turnover of kr 60 mill. Thanks to the algorithms that worked hard to keep the price down. 😡 The pros at Aker Brygge are picking up cheap shares in abundance. Bottom fishing is often profitable. Big capital is at work 😡😡. But we will shake this off. New juicy stock exchange announcements might come in this week...and a good breakout upwards at 5.95 and 🔥🔥🔥🔥🔥This is better than 20% up. Massive turnover, and many securities changing hands, I cannot in my wildest imagination see us seeing the 4-level again unless something negative happens.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHave been in since it was called Nano, and lost a bit on it. Have been in after they changed their name to Thor Medical. Now the risk is minimized. A company with the same technology may emerge, but Thor is first out, and there will be room for more. The demand for Thorium will increase as existing and new companies get approval for their cancer medicines. That can happen at any time.I was so lucky to be part of NANO's fantastic journey from when the price was about 14-16 until I sold out at around 114, a good year later!! though it probably had a peak at around 120!. As far as I remember. Hope and believe the story can repeat itself :-)
- ·4 t sittenhttps://youtu.be/G7N_DWUxLXw?is=7sIGK6n87SHns3Bv Jasper in the studio at FA. Sounds positive all the way through👍
- ·7 t sittenAsked chatgpt to estimate stock price in 10 years. Where A1-2 and global are involved. This was a slightly more simplified answer: ### Thor Medical – realistic 10-year scenario (2036) **Assumptions** * AlphaOne: 21 000 doses. * AlphaTwo: approx. 200 000 doses. * AlphaGlobal: >1 million doses. * Price per dose follows 2,5 % inflation: **16 000 kr → approx. 20 500 kr in 2036**. * Two share issues totaling approx. **1 billion kr**, so that the number of shares increases from around **330 to approx. 500 million**. ### Timeline * **2026–2027:** AlphaOne in commercial operation. * **2028:** Share issue and construction start AlphaTwo. * **2030:** AlphaTwo in production. * **2032:** New share issue/partnership for AlphaGlobal. * **2034–2035:** AlphaGlobal in operation. * **2036:** Full global capacity. ### Possible financials in 2036 * **Revenue:** 22–26 billion kr. * **Net profit:** 9–12 billion kr. * **Market capitalization:** 180–250 billion kr (P/E 20–25). * **Share price:** **360–500 kr** (with approx. 500 million shares). ### Realistic drawbacks * Share issues will likely dilute current shareholders. * Price per dose may fall if competition increases. * Construction of new factories may become more expensive or delayed. * Approvals and customer adoption may take longer than planned. * Several companies are developing alternative production methods and isotopes. ### Conclusion If Thor Medical succeeds in becoming a dominant player and implements the scaling as planned, a **long-term price range of 350–500 kr** appears as an optimistic, but still plausible scenario. If growth is weaker or dilution greater than assumed, the valuation may be significantly lower. Conversely, an even stronger market position and higher profitability could yield higher values than this range.There are so many scenarios and limitations that ChatGPT does not account for. The most common (in the West) are directed issues to only larger shareholders (note that this is something Thor has not done so far), the company can be acquired where we small investors are kicked out, any positive cash flow quickly faces strong competition, even better and newer technology than Thor's method will emerge. Furthermore, there are already approximately 360 million shares today, and with A-Two and A-Global, this will require large investments, meaning far more than a total of 500 million shares. We will be heavily diluted, and with dilution, the share price will normally fall. I believe that for us small investors, a horizon of 2-5 years is more sensible, and then we can extend the horizon when one sees that the landscape allows for it. My prediction is that we will be rising in the 6s this autumn, and rising in the 7s after the Q4 report in February 2027. Thor must now prove its position and its cash flow. The time for only expectations, faith, hope, and love is now over. Only real money in the till matters from this autumn, P/E.
- ·8 t sittenUp approx 6% today kr 5.64 is somewhat weak with such very good news and a healthy turnover of kr 60 mill. Thanks to the algorithms that worked hard to keep the price down. 😡 The pros at Aker Brygge are picking up cheap shares in abundance. Bottom fishing is often profitable. Big capital is at work 😡😡. But we will shake this off. New juicy stock exchange announcements might come in this week...and a good breakout upwards at 5.95 and 🔥🔥🔥🔥🔥This is better than 20% up. Massive turnover, and many securities changing hands, I cannot in my wildest imagination see us seeing the 4-level again unless something negative happens.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
160 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sittenHave been in since it was called Nano, and lost a bit on it. Have been in after they changed their name to Thor Medical. Now the risk is minimized. A company with the same technology may emerge, but Thor is first out, and there will be room for more. The demand for Thorium will increase as existing and new companies get approval for their cancer medicines. That can happen at any time.I was so lucky to be part of NANO's fantastic journey from when the price was about 14-16 until I sold out at around 114, a good year later!! though it probably had a peak at around 120!. As far as I remember. Hope and believe the story can repeat itself :-)
- ·4 t sittenhttps://youtu.be/G7N_DWUxLXw?is=7sIGK6n87SHns3Bv Jasper in the studio at FA. Sounds positive all the way through👍
- ·7 t sittenAsked chatgpt to estimate stock price in 10 years. Where A1-2 and global are involved. This was a slightly more simplified answer: ### Thor Medical – realistic 10-year scenario (2036) **Assumptions** * AlphaOne: 21 000 doses. * AlphaTwo: approx. 200 000 doses. * AlphaGlobal: >1 million doses. * Price per dose follows 2,5 % inflation: **16 000 kr → approx. 20 500 kr in 2036**. * Two share issues totaling approx. **1 billion kr**, so that the number of shares increases from around **330 to approx. 500 million**. ### Timeline * **2026–2027:** AlphaOne in commercial operation. * **2028:** Share issue and construction start AlphaTwo. * **2030:** AlphaTwo in production. * **2032:** New share issue/partnership for AlphaGlobal. * **2034–2035:** AlphaGlobal in operation. * **2036:** Full global capacity. ### Possible financials in 2036 * **Revenue:** 22–26 billion kr. * **Net profit:** 9–12 billion kr. * **Market capitalization:** 180–250 billion kr (P/E 20–25). * **Share price:** **360–500 kr** (with approx. 500 million shares). ### Realistic drawbacks * Share issues will likely dilute current shareholders. * Price per dose may fall if competition increases. * Construction of new factories may become more expensive or delayed. * Approvals and customer adoption may take longer than planned. * Several companies are developing alternative production methods and isotopes. ### Conclusion If Thor Medical succeeds in becoming a dominant player and implements the scaling as planned, a **long-term price range of 350–500 kr** appears as an optimistic, but still plausible scenario. If growth is weaker or dilution greater than assumed, the valuation may be significantly lower. Conversely, an even stronger market position and higher profitability could yield higher values than this range.There are so many scenarios and limitations that ChatGPT does not account for. The most common (in the West) are directed issues to only larger shareholders (note that this is something Thor has not done so far), the company can be acquired where we small investors are kicked out, any positive cash flow quickly faces strong competition, even better and newer technology than Thor's method will emerge. Furthermore, there are already approximately 360 million shares today, and with A-Two and A-Global, this will require large investments, meaning far more than a total of 500 million shares. We will be heavily diluted, and with dilution, the share price will normally fall. I believe that for us small investors, a horizon of 2-5 years is more sensible, and then we can extend the horizon when one sees that the landscape allows for it. My prediction is that we will be rising in the 6s this autumn, and rising in the 7s after the Q4 report in February 2027. Thor must now prove its position and its cash flow. The time for only expectations, faith, hope, and love is now over. Only real money in the till matters from this autumn, P/E.
- ·8 t sittenUp approx 6% today kr 5.64 is somewhat weak with such very good news and a healthy turnover of kr 60 mill. Thanks to the algorithms that worked hard to keep the price down. 😡 The pros at Aker Brygge are picking up cheap shares in abundance. Bottom fishing is often profitable. Big capital is at work 😡😡. But we will shake this off. New juicy stock exchange announcements might come in this week...and a good breakout upwards at 5.95 and 🔥🔥🔥🔥🔥This is better than 20% up. Massive turnover, and many securities changing hands, I cannot in my wildest imagination see us seeing the 4-level again unless something negative happens.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt